IHAM
ITOS

Integral Health Asset Management’s iTeos Therapeutics ITOS Stock Holding History

Integral Health Asset Management’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-180,000
Closed -$2.45M – 87
2023
Q1 		$2.45M Sell
180,000
-90,000
-33% -$1.61M 0.49% 58
2022
Q4 		$5.27M Buy
270,000
+75,000
+38% +$1.47M 1.11% 34
2022
Q3 		$3.71M Buy
195,000
+38,447
+25% +$886K 0.72% 47
2022
Q2 		$3.23M Buy
156,553
+71,553
+84% +$1.7M 0.66% 49
2022
Q1 		$2.73M Buy
85,000
+35,000
+70% +$1.27M 0.71% 51
2021
Q4 		$2.33M Buy
+50,000
New +$1.66M 0.64% 48

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Integral Health Asset Management's ITOS Position: Q2 2023 in Review

Integral Health Asset Management sold out of iTeos Therapeutics (ITOS) in Q2 2023, closing a stake of 180,000 shares — an estimated $2.45M sold.

Integral Health Asset Management first reported a position in ITOS in Q4 2021 and held it in 6 quarters. The position peaked at $5.27M in Q4 2022. 146 funds tracked by Wall St. Rank hold ITOS as of Q2 2023.

  • Integral Health Asset Management reported no remaining iTeos Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Integral Health Asset Management sold 180,000 iTeos Therapeutics shares in Q2 2023, an estimated $2.45M.
  • Integral Health Asset Management first reported a position in iTeos Therapeutics in Q4 2021 and held it in 6 quarters.
  • Integral Health Asset Management's iTeos Therapeutics position peaked at $5.27M in Q4 2022.
  • 146 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2023.

Based on Integral Health Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.